APA

Ricceri F., Pescitelli L., Lazzeri L., Di Cesare A. & Prignano F. (20190513). Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Chicago

Ricceri F, Pescitelli L, Lazzeri L, Di Cesare A and Prignano F. 20190513. Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Harvard

Ricceri F., Pescitelli L., Lazzeri L., Di Cesare A. and Prignano F. (20190513). Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. : Journal of the European Academy of Dermatology and Venereology : JEADV.

MLA

Ricceri F, Pescitelli L, Lazzeri L, Di Cesare A and Prignano F. Reply: adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. : Journal of the European Academy of Dermatology and Venereology : JEADV. 20190513.